Know How the Emerging Trends Changes the Future of API Manufacturing

By -

This report analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia, and the Rest of the World (RoW).

(EMAILWIRE.COM, July 06, 2018 ) Browse 369 market data tables and 46 figures spread through 312 pages and in-depth TOC on “Active Pharmaceutical Ingredients/API Market”
https://www.marketsandmarkets.com/Market-Reports/API-Market-263.html
Early buyers will receive 10% customization on this report.

The global active pharmaceutical ingredients market is expected to reach USD 213.97 Billion by 2021 from USD 157.95 Billion in 2016, growing at a CAGR of 6.3% from 2016 to 2021.

Major factors contributing to the growth of the active pharmaceutical ingredients market include increasing incidence of chronic diseases, rising prevalence of cancer, technological advancements in API manufacturing, growing importance of generics, rapidly increasing geriatric population, increase in abbreviated new drug applications (ANDA) and increasing uptake of biopharmaceuticals. Government initiatives to encourage adoption of generics also provide an impetus for the growth of this market.

For instance, in 2008, the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, launched the Jan Aushadhi Scheme (Public Medicine Scheme) for providing quality medicines to the masses at affordable prices. Under this initiative, the government set up Jan Aushadhi stores to provide generic drugs to patients.

Download the PDF Brochure@
https://www.marketsandmarkets.com/pdfdownload.asp?id=263

Similarly, The European Union’s decentralized procedure (DCP) for drug approval is an effective system for cross-border collaboration on the authorization of medicines. This is being used as a model for a number of new global initiatives in the harmonization of pharmaceutical regulatory standards. The implementation of such standards in turn is expected to drive the adoption of generic drugs.

Emerging biosimilars market, increasing scope for HPAPIs, emerging markets and emerging technologies have opened an array of opportunities for the active pharmaceutical ingredients market. However, factors such as a stringent regulatory requirements and unfavorable drug price control policies across various countries may restrain the growth of this market.
Based on type, the market is segmented into innovative and generic APIs.

On the basis of type of manufacture, the APIs market is categorized into two segments, captive manufacturer and merchant manufacturer. On the basis of type of synthesis, the APIs market is segmented into synthetic APIs and biotech APIs. On the basis of type of drug, the APIs market is segmented into prescription and over-the-counter APIs.

On the basis of therapeutic application, the APIs market is further segmented into oncology, cardiovascular diseases, diabetes, endocrinology, central nervous system and neurological diseases and other therapeutic applications.

Get the Sample Pages@
https://www.marketsandmarkets.com/requestsample.asp?id=263

Prominent players in the active pharmaceutical ingredients market include Pfizer, Inc. (U.S.), Novartis International AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (U.S.), GlaxoSmithKline plc (U.K.), Merck & Co., Inc. (U.S.) and AbbVie Inc. (U.S.).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Read other news from MarketsandMarkets™

Timing Devices Market Size, Share, Revenue Trends & Forecast to 2030

MarketsandMarkets™ - Sep 18, 2023
Timing Devices Market by Type (Oscillators, Atomic Clocks, Clock Generators, Clock Buffers, Jitter Attenuators), Material (Crystal, Silicon, Ceramic), Vertical (Consumer Electronics, Automotive) and Region - Global Forecast to 2030 ...Read more

Artificial Intelligence Market Segmented by Product, Top Manufacturers, Geography Trends & Growth Opportunity to 2030

MarketsandMarkets™ - Sep 18, 2023
Artificial Intelligence technology such as machine learning, natural language processing, computer vision, and others are revolutionizing various sectors, including healthcare, finance, manufacturing, and retail. ...Read more

Digital PCR (dPCR) and Real-time PCR (qPCR) Market worth $12.4 billion by 2028, at a CAGR of 7.8%.

MarketsandMarkets™ - Sep 18, 2023
"Digital PCR (dPCR) and Real-time PCR (qPCR) Market by Product (Instruments, Reagents & Consumables, Software & Services), Application (Clinical, Research, Forensic), End User (Hospital, Diagnostic Labs, Pharma, Biotech, CROs) - Global Forecast to 2028". ...Read more